We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Renal Cell Carcinoma
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
Eric Wiedower
Jul 21, 2015
It would be unusual for prostate cancer to metastasize to the brain. We have biopsy proven metastatic ccRCC to axillary LN. Given his extensive smoking history, I would push for bronchoscopy with biopsy again for tissue diagnosis vs CT guided biopsy of lung mass. Brain lesion would need XRT one way or the other. Would use pathology from the lung (lung primary vs RCC met) to dictate which systemic therapy to use as lung cancer, if present, could be more immediately life threatening than his RCC.
George Yaghmour
Sep 04, 2015
Very interesting and challenging case, obviously it is unlikely to be prostate cancer, Biopsy of the axillary and brain mass showed clear cell feature of unknown origin, CK7-, CK20-,CD10+ which is likely renal cell of unknown primary which has been reported and addressed before. RCC IHC is negative and adding PAX-8 and Vimentin staining should be considered for further confirmation of the diagnosis and if it RCC TKI would be an option. John D. Hainsworth and his colleagues reported as an ASCO abstract in 2013 that Renal cell carcinoma (RCC) can be presented as cancer of unknown primary (CUP), diagnosed by molecular tumor profiling (MTP) using (RT-PCR 92-gene assay, CancerTYPE ID, bioTheranostics, Inc.). Molecular changed for RCC has been reported like nicotinamide N-methyltransferase (NNMT), L-plastin (LCP1) and nonmetastatic cells 1 protein (NM23A). RCC is a subset of CUP which can be diagnosed by MTP. RCC is usually not suspected in the absence of clear cell features, and occult RCC appears to commonly be the papillary subtype. RCC IHC may be diagnostic in some CUP tumors, but may be omitted in the initial pathologic evaluation. CUP-RCC pts are important to identify as they may benefit from standard RCC targeted therapies, and respond poorly to empiric chemotherapy.
Andrew Fintel
Sep 14, 2015
Thank you for your input on this case. Something like a CancerTYPE ID would be helpful here. For this patient, given that he has two cancers that have both been studied using Nivolumab as treatment, we proceeded with starting him on this mainly because we know that Squamous Cell Carcinoma will respond to Nivolumab from the Checkmate 017 trial vs docetaxel, but also RCC has shown promise in phase II trials with good response at 2 and 3 years. In this case, the pathology showed that both tumors (Lung and Axilla) were positive for PD-1.
Apr 25, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Andrew
Fintel
DO
Eric Wiedower
Jul 21, 2015
George Yaghmour
Sep 04, 2015
Andrew Fintel
Sep 14, 2015
Apr 25, 2024
Pending Moderator approval.